2025 China Anti-Tnf-A Monoclonal Antibody Market Revenue Opportunities Report
Description
The 2025 China Anti-Tnf-A Monoclonal Antibody Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-TNF-a Monoclonal Antibody Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Anti-TNF-α monoclonal antibody market in China are AbbVie, Innovent Biologics, Bio-Thera Solutions, and Henlius. AbbVie’s flagship drug, adalimumab (Humira), entered China in 2012 and is a fully humanized anti-TNF-α monoclonal antibody widely used for rheumatoid arthritis and other autoimmune diseases. About 20 Chinese companies, including Innovent, Bio-Thera, and Henlius, are actively developing biosimilars of adalimumab and other monoclonal antibodies, contributing significantly to the growing domestic market and increasing accessibility for patients.
In addition, Junshi Biosciences, a major Shanghai-based biopharmaceutical company, is developing UBP1211, a TNF-α targeting monoclonal antibody approved for clinical trials by China’s NMPA. Junshi is expanding its production capacity and is publicly listed on the Hong Kong stock exchange, reflecting its growing influence in the Chinese biologics sector. WuXi Biologics also plays an active role in antibody drug innovation and partnerships within China, supporting the advancement of biologics manufacturing and novel therapies, including collaborations on antibody engineering platforms. These companies collectively drive the innovation, production, and commercialization of anti-TNF-α monoclonal antibodies in China’s rapidly evolving market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-TNF-a Monoclonal Antibody Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Anti-TNF-α monoclonal antibody market in China are AbbVie, Innovent Biologics, Bio-Thera Solutions, and Henlius. AbbVie’s flagship drug, adalimumab (Humira), entered China in 2012 and is a fully humanized anti-TNF-α monoclonal antibody widely used for rheumatoid arthritis and other autoimmune diseases. About 20 Chinese companies, including Innovent, Bio-Thera, and Henlius, are actively developing biosimilars of adalimumab and other monoclonal antibodies, contributing significantly to the growing domestic market and increasing accessibility for patients.
In addition, Junshi Biosciences, a major Shanghai-based biopharmaceutical company, is developing UBP1211, a TNF-α targeting monoclonal antibody approved for clinical trials by China’s NMPA. Junshi is expanding its production capacity and is publicly listed on the Hong Kong stock exchange, reflecting its growing influence in the Chinese biologics sector. WuXi Biologics also plays an active role in antibody drug innovation and partnerships within China, supporting the advancement of biologics manufacturing and novel therapies, including collaborations on antibody engineering platforms. These companies collectively drive the innovation, production, and commercialization of anti-TNF-α monoclonal antibodies in China’s rapidly evolving market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
